# US 2021/0198748 A1 · Gene expression assay for measurement of dna mismatch repair deficiency

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198748 A1
- Document ID: US20210198748A1
- Status: Published application
- Kind: A1
- Application number: 17/086,842
- Filed: 2020-11-02
- Published: 2021-07-01
- Earliest claimed: 2018-05-04
- Assignees: Bruker Spatial Biology, Inc.
- Applicants: NanoString Technologies, Inc.
- Inventors: Patrick DANAHER; Sarah WARREN
- Web page: https://patentgrep.com/patent/US20210198748A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present disclosure relates to methods using gene expression measurements to identify mismatch repair deficiency, microsatellite instability and hypermutation in a subject.

## Claims

### Claim 1

A method of treating cancer in a subject identified as having mismatch repair deficiency, the method comprising administering to the subject identified as having mismatch repair deficiency at least one treatment, wherein the subject is identified as having mismatch repair deficiency by a method comprising
a) measuring the gene expression level of at least one gene comprising MLH1, MSH2, MSH6 or PMS2 in a tumor sample from the subject;
b) determining for each of the at least one gene a score Z, wherein Z=(x−μ1)/σ1, wherein x is the log-transformed normalized expression of the at least one gene, μ1 is the mean of the log-transformed normalized expression of the at least one gene in non-hypermutated samples, and σ1 is the standard deviation of the log-transformed normalized expression of the at least one gene in non-hypermutated samples;
c) determining a score MLS, wherein MLS=(Zm+c1)/c2, wherein Zm is the minimum Z score of the at least one gene, and wherein
c1 is 0 and c2 is 1 when one gene is used,
c1 is 0.56 and c2 is 0.83 when two genes are used,
c1 is 0.85 and c2 is 0.75 when three gene are used, or
c1 is 1.03 and c2 is 0.70 when four genes are used;
d) comparing the MLS score with a predetermined cutoff value, wherein the cutoff value identifies mismatch repair deficiency in a subject with at least 95% specificity; and
e) identifying the presence of mismatch repair deficiency in the subject when the MLS score is equal to or greater than the predetermined cutoff value.

### Claim 2 (depends on 1)

The method of claim 1, wherein the cutoff value identifies mismatch repair deficiency in a subject with at least 99% specificity.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the cutoff value is 1.645.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cutoff value is 2.326.

### Claim 6 (depends on 1)

The method of claim 1, wherein the cutoff value is 2.576.

### Claim 7 (depends on 1)

The method of claim 1, wherein the at least one gene comprises MLH1.

### Claim 8 (depends on 1)

The method of claim 1, wherein the at least one gene comprises each of MLH1, MSH2, MSH6 and PMS2.

### Claim 9

A method of treating cancer in a subject identified as having mismatch repair deficiency, the method comprising administering to the subject identified as having mismatch repair deficiency at least one treatment, wherein the subject is identified as having mismatch repair deficiency by a method comprising
a) measuring the gene expression level of at least one gene comprising EPM2AIP1, TTC30A, SMAP1, RNLS, WNT11, SFXN1, SREBF1, TYMS, EIF5AL1, or WDR76 in a tumor sample from the subject;
b) determining a score HPS, wherein HPS=(y−μ2)/σ2, wherein y=Σi=110yiwi, wherein yi is the log-transformed normalized expression of the at least one gene i in the tumor sample and wi is the prespecified weight for gene i, μ2 is the mean of the linear combination of the log-transformed normalized expression of the at least one gene in non-hypermutated samples, and σ2 is the standard deviation of the linear combination of the log-transformed normalized expression of the at least one gene in non-hypermutated samples;
c) comparing the HPS score with a predetermined cutoff value, wherein the cutoff value identifies mismatch repair deficiency in a subject with at least 95% specificity; and
d) identifying the presence of mismatch repair deficiency in the subject when the HPS score is equal to or greater than the predetermined cutoff value.

### Claim 10 (depends on 9)

The method of claim 9, wherein the weight wi for the at least one gene is
Gene
Weight
EPM2AIP1
−0.31218
TTC30A
−0.19894
SMAP1
−0.1835
RNLS
−0.19023
WNT11
−0.11515
SFXN1
0.214676
SREBF1
0.194835
TYMS
0.206972
EIF5AL1
0.194935
WDR76
0.188582

### Claim 11 (depends on 9)

The method of claim 9, wherein the cutoff value identifies mismatch repair deficiency in a subject with at least 99% specificity.

### Claim 12

(canceled)

### Claim 13 (depends on 9)

The method of claim 9, wherein the cutoff value is 1.645.

### Claim 14 (depends on 9)

The method of claim 9, wherein the cutoff value is 2.326.

### Claim 15 (depends on 9)

The method of claim 9, wherein the cutoff value is 2.576.

### Claim 16 (depends on 9)

The method of claim 9, wherein the at least one gene comprises each of EPM2AIP1, TTC30A, SMAP1, RNLS, WNT11, SFXN1, SREBF1, TYMS, EIF5AL1 and WDR76

### Claim at position 17

-32. (canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein the treatment comprises immunotherapy.

### Claim 34 (depends on 1)

The method of claim 1, wherein the treatment comprises administering to the subject checkpoint inhibitors.

### Claim 35 (depends on 1)

The method of claim 1, wherein the treatment comprises administering to the subject pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab or a combination thereof.

### Claim 36 (depends on 1)

The method of claim 1, wherein the treatment comprises administering to the subject pidilizumab, REGN2810, AMP-224, MEDI0680, PDR001, CT-001 or a combination thereof.

### Claim 37 (depends on 1)

The method of claim 1, wherein the treatment comprises administering to the subject a CTLA4 antibody.

### Claim 38 (depends on 37)

The method of claim 37, wherein the CTLA4 antibody comprises ipilimumab, tremelimumab or a combination thereof.

### Claim 39

(canceled)
